Origin Trial Investigators, Gerstein, H., Yusuf, S., Riddle, M.C., Ryden, L., et al. (2008) Rationale, Design, and Baseline Characteristics for a Large International Trial of Cardiovascular Disease Prevention in People with Dysglycemia: The ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention). American Heart Journal, 155, 26-32.

has been cited by the following article:

• TITLE: Efficacy and Safety of Patient-Led Dosage Adjustments of Insulin Glargine: A Preliminary Report of Basal-Supported Oral Therapy for Japanese Type 2 Diabetes Patients

  AUTHORS: Shuhei Nakanishi, Mitsunobu Kubota, Rui Kishimoto

  KEYWORDS: Glargine, Self-Titration, BOT, T2DM, Insulin

  JOURNAL NAME: Journal of Diabetes Mellitus, Vol.4 No.2, April 21, 2014

  ABSTRACT: To evaluate the clinical utility for simple patient administered dose adjustment methods of insulin glargine during outpatient visits compared with a physician managed titration, changes in HbA1c and total daily dose of insulin were evaluated in 23 patients by dividing patients into physician-led (PL) group and self-titration (ST) group who were newly administered glargine basal-supported oral therapy (BOT) while continuing oral antidiabetic drugs at the discretion of their attending physician during regular outpatient visits. In the PL group, one month after initiation of glargine, HbA1c followed a declining trend, although this was not significant (P = 0.07), and decreased significantly after two and three months (P